Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis

International Journal of Dermatology

Volumn 48, Issue 11, 2009, Pages 1147-1156

  Kimball, Alexa Boer ^a   Wu, Ying ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE;

ALCOHOL ABUSE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; OBESITY; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PSORIASIS; REVIEW; SMOKING;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; PSORIASIS; RISK FACTORS;

EID: 70449346518     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04075.x     Document Type: Review

References (83)

1. About Psoriasis. Statistics. http://www.psoriasis.org/about/stats/, Available at: [accessed 23 March 2007]
2. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
3. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005, 64(Suppl. 2):ii30-ii36.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
6. Raychaudhuri SP, Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis 2000, 66:348-352.
7. Weinberg JM. Lifestyle issues and psoriasis. Cutis 2006, 78:160.
8. McDonald CJ, Calabresi P. Thromboembolic disorders associated with psoriasis. Arch Dermatol 1973, 107:918.
9. McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med 1973, 288:912.
10. McDonald CJ, Calabresi P. Complication of psoriasis. J Am Med Assoc 1973, 224:629.
11. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978, 99:469-475.
12. McDonald CJ. Cardiovascular disease in psoriasis. J Invest Dermatol 1989, 92:646-647.
13. Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986, 172:298-304.
14. Mallbris L, Akre O, Granath F. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004, 19:225-230.
15. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1380 patients. J Invest Dermatol 1988, 91:197-201.
16. Prodanovich S, Ma F, Taylor JR. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005, 52:262-267.
17. Wakkee M, Thio HB, Prens EP. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007, 190:1-9.
18. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2006, 20:52-55.
19. Gelfand JM, Neimann AL, Shin DB. Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc 2006, 296:1735-1741.
20. Mallbris L, Ritchlin CT, Ståhle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006, 8:355-363.
21. Gisondi P, Tessari G, Conti A. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007, 157:68-73.
22. Oztürkcan S, Ermertcan AT, Sekuri C. Cardiovascular findings in patients with psoriasis. Ann Saudi Med 2006, 26:159-161.
23. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995, 32:982-986.
24. Ludwig RJ, Herzog C, Rostock A. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007, 156:271-276.
25. Inerot A, Enerback C, Enlund F. Collecting a set of psoriasis family material through a patient organisation; clinical characterisation and presence of additional disorders. BMC Dermatol 2005, 5:10.
26. Neimann AL, Shin DB, Wang X. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006, 55:829-835.
27. Vanizor Kural B, Orem A, Çimsit G. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003, 328:71-82.
28. Vanizor Kural B, Orem A, Çimsit G. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003, 332:23-30.
29. Piskin S, Gurkok F, Ekuklu G. Serum lipid levels in psoriasis. Yonsei Med J 2003, 44:24-26.
30. Rocha-Pereira P, Santos-Silva A, Rebelo I. Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001, 303:33-39.
31. Seishima M, Seishima M, Mori S. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol 1994, 130:738-742.
32. Uyanik BS, Ari Z, Onur E. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002, 40:65-68.
33. Vahlquist C, Michaëlsson G, Vessby B. Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol 1987, 67:12-15.
34. Mallbris L, Granath F, Hamsten A. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006, 54:614-621.
35. Reynoso-von Drateln C, Martínez-Abundis E, Balcázar-Muñoz BR. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003, 48:882-885.
36. Pietrzak A, Lecewicz-Torun B, Chodorowska G. Serum lipid profile in psoriatic females. Ann Univ Marie Curie Sklodowska [Med] 1999, 54:401-406.
37. Eikelboom JW, Lonn E, Genest J. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999, 131:363-375.
38. Malerba M, Gisondi P, Radaeli A. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006, 155:1165-1169.
39. Lonn E, Yusuf S, Arnold MJ. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354:1567-1577.
40. Mendall MA, Patel P, Ballam L. C reactive protein and its relation to cardiovascular risk factors: a population based cross-sectional study. Br Med J 1996, 312:1061-1065.
41. Mitra B, Panja M. High sensitive C-reactive protein: a novel biochemical marker and its role in coronary artery disease. J Assoc Physicians India 2005, 53:25-32.
42. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003, 92:10i-18i.
43. Ridker PM. C-reactive protein, inflammation, and cardiovascular disease: clinical update. Tex Heart Inst J 2005, 32:384-386.
44. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007-2011.
45. Koenig W, Sund M, Fröhlich M. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984-92. Circulation 1999, 99:237-242.
46. Milazzo D, Biasucci LM, Luciani N. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999, 84:A9-461.
47. Haverkate F, Thompson SG, Pyke SD. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997, 349:462-466.
48. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004, 18:180-183.
49. Rocha-Pereira P, Santos-Silva A, Rebelo I. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004, 150:917-928.
50. Pearce DJ, Morrison AE, Higgins KB. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat 2005, 16:319-323.
51. Kimhi O, Caspi D, Bornstein NM. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007, 36:203-209.
52. Shapiro J, Cohen AD, David M. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007, 56:629-634.
53. Binazzi M, Calandra P, Lisi P. Statistical association between psoriasis and diabetes: further results. Arch Dermatol Res 1975, 254:43-48.
54. Tominaga M, Eguchi H, Manaka H. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
55. Rao SS, Disraeli P, McGregor T. Impaired glucose tolerance and impaired fasting glucose. Am Fam Physician 2004, 69:1961-1968.
56. Brownlee M. A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest 2003, 112:1788-1790.
57. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001, 86:4047-4058.
58. Porte D, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 2001, 50(Suppl. 1):S160-S163.
59. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997, 50:191-197.
60. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453-458.
61. Ucak S, Ekmekci TR, Basat O. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 2006, 20:517-522.
62. Seckin D, Tokgözoglu L, Akkaya S. Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis?. J Am Acad Dermatol 1994, 31:445-449.
63. Brenelli SL, Moraes AM, Monte-Alegre S. Insulin resistance in psoriasis. Braz J Med Biol Res 1995, 28:297-301.
64. McGowan JW, Pearce DJ, Chen J. The skinny on psoriasis and obesity. Arch Dermatol 2005, 141:1601-1602.
65. Marino MG, Carboni I, De Felice C. Risk factors for psoriasis: a retrospective study on 501 outpatients clinical records. Ann Ig 2004, 16:753-758.
66. Naldi L, Chatenoud L, Linder D. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005, 125:61-67.
67. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses' Health Study II. Arch Intern Med 2007, 167:1670-1675.
68. Herron MD, Hinckley M, Hoffman MS. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005, 141:1527-1534.
69. Mills CM, Srivastava ED, Harvey IM. Smoking habits in psoriasis: a case-control study. Br J Dermatol 1992, 127:18-21.
70. Fortes C, Mastroeni S, Leffondré K. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005, 141:1580-1584.
71. Gupta MA, Gupta AK, Watteel GN. Cigarette smoking in men may be a risk factor for increased severity of psoriasis of the extremities. Br J Dermatol 1996, 135:859-860.
72. Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol 1999, 135:1479-1484.
73. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999, 135:1490-1493.
74. Zimmerman GM. Alcohol and psoriasis: a double burden. Arch Dermatol 1999, 135:1541-1542.
75. Naldi L, Parazzini F, Brevi A. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992, 127:212-217.
76. Zhang X, Wang H, Te-Shao H. Frequent use of tobacco and alcohol in Chinese psoriasis patients. Int J Dermatol 2002, 41:659-662.
77. Fox CS, Coady S, Sorlie PD. Trends in cardiovascular complications of diabetes. J Am Med Assoc 2004, 292:2495-2499.
78. Ninomiya JK, L'Italien G, Criqui MH. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004, 109:42-46.
79. Yusuf S, Hawken S, Ounpuu S. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640-1649.
80. Kimball AB, Szapary P, Li S. High prevalence and under-diagnosis of cardiovascular risk factors among psoriasis patients in a clinical trial population. American Academy of Dermatologists Summer Academy Meeting, July 30-August 3, 2008, Chicago, IL Poster presented at
81. Feldman SR, Ravis S, Moran WP. Patients seen in a dermatology clinic have unmet preventive health care needs. J Am Acad Dermatol 2001, 44:706-709.
82. Gelfand JM, Shin DB, Neimann AL. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006, 126:2194-2201.
83. Scarpa R, Oriente P, Pucino A. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984, 23:246-250.